The Economic Times Healthcare and Biotech News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Delhi HC: No customs duties on rare disease medicines
Delhi High Court clarifies no custom duties on medicines for rare diseases, ensuring expedited clearance and access to necessary treatments. Justice Pratibha Singh's order emphasizes swift clearance by customs authorities, avoiding unnecessary delays. The ruling follows a Finance Ministry notification granting full exemption from basic customs duty on drugs and food for rare diseases. The decision benefits children with conditions like Duchenne Muscular Dystrophy, easing the financial burden of treatment. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 4, 2024 Category: Pharmaceuticals Source Type: news

Delhi HC bars Natco Pharma from selling cancer drug Olaparib
The Delhi High Court has prohibited Natco Pharma from producing and selling the cancer drug Olaparib, marketed as 'BRACANAT' or under any other name, until further notice. The court's decision came in response to a lawsuit by Kudos Pharmaceuticals, which claimed that Natco was infringing on its patent for Olaparib. The court found Natco's challenge to the patent's validity unconvincing, leading to the injunction. Natco had sought to revoke Kudos' patent only after the lawsuit was filed, despite no previous opposition to it. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 4, 2024 Category: Pharmaceuticals Source Type: news

Cadila Pharma introduces vaccine for seasonal flu
The new vaccine targets four strains of the influenza virus subtype -A and B, responsible for seasonal epidemics, the drug firm said in a statement. Developed using proprietary technology employing nano-sized particles, the vaccine mimics the external structure of the virus without containing intact genetic material, it added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 4, 2024 Category: Pharmaceuticals Source Type: news

Over 12 mn Indian children now obese: Key points from scary Lancet study
(Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 4, 2024 Category: Pharmaceuticals Source Type: news

Biocon Biologics settles patent issue; paves way for launch of biosimilar product in Canada
Biocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalmology product for neovascular and age-related macular degeneration, in Canada by July 1, 2025. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 4, 2024 Category: Pharmaceuticals Source Type: news

Joint steps, sharing of info in Niti road map for future pandemics
India is developing a pandemic preparedness programme with NITI Aayog, focusing on coordination, joint exercises, information sharing, and strengthening data availability. The program aims to ensure equitable resource distribution, address vulnerability, and collaborate globally for early detection and containment of pandemics. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 3, 2024 Category: Pharmaceuticals Source Type: news

Suven, with Cohance and more, wants to become a CDMO powerhouse: Annaswamy Vaidheesh, executive chairman
"We want to be a diversified, end-to-end capability outsourcing partner, serving customers from development to commercial scale. Doing this reliably & consistently across a wide range of chemistries, that's where the opportunity is," said Annaswamy Vaidheesh, executive chairman of Suven in an interview to ET. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 1, 2024 Category: Pharmaceuticals Source Type: news

Takeda to soon start trials in India for dengue vaccine
Takeda Pharmaceuticals' dengue vaccine assumes significance since the first vaccine ever licensed for dengue, developed by French drugmaker Sanofi Pasteur, met with failure as it only helped people who had been previously infected with the virus. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 29, 2024 Category: Pharmaceuticals Source Type: news

Biocon Biologics inks licence pact with Janssen for biosimilar product
The agreement licenses the company to launch in the US in February 2025, once approved by the US Food and Drug Administration(USFDA), Biocon Biologics said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 29, 2024 Category: Pharmaceuticals Source Type: news

Suven-Cohance Lifesciences merger announced to create 1st listed PE-led contract manufacturer in Indian pharma
Suven has been 50% owned by Advent since 2022 acquisition, with the remaining with public and institutional shareholders while Cohance is wholly owned by the PE group. Now post merger, Advent will own 66.7% in the combined entity and the public shareholders the rest. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 29, 2024 Category: Pharmaceuticals Source Type: news

Weight-loss drug may be launched in India next year, says Eli Lilly CEO David Ricks
US drug maker Eli Lilly plans to launch its weight-loss drugs Zepbound and Mounjaro in India next year. The company is considering pricing based on supply and volume expansion. Eli Lilly CEO David Ricks suggests focusing on digital services in the Indian healthcare industry to encourage innovation and improve access to healthcare. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 29, 2024 Category: Pharmaceuticals Source Type: news

Eli Lilly could launch obesity drug in India next year, CEO says
Eli Lilly plans to launch its diabetes and obesity drug, Mounjaro, in India next year. The drug contains tirzepatide and is sold as Zepbound in the US. The global market for GLP-1 receptor agonists, including Mounjaro, Wegovy, and Ozempic, is expected to reach $100 billion by the end of the decade. Lilly's drugs as well as Danish rival Novo Nordisk's in-demand Wegovy and Ozempic are therapies known as GLP-1 receptor agonists, which were developed to control blood sugar in patients with type 2 diabetes. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 28, 2024 Category: Pharmaceuticals Source Type: news

KKR considers selling stake in India’s $3 billion JB Pharma
KKR & Co. is reportedly considering selling its 53.8% controlling stake in Indian pharmaceutical company JB Chemicals & Pharmaceuticals Ltd. The US private equity firm is said to be exploring options and seeking financial advisers for a potential sale, with other buyout firms and industry players expressing preliminary interest. JB Pharma's shares have seen a 68% increase in the past year, valuing the company at just over $3 billion. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 28, 2024 Category: Pharmaceuticals Source Type: news

Lilly could launch obesity drug in India next year, CEO says
Eli Lilly plans to launch its obesity drug, tirzepatide, in India next year. The drug, also known as Mounjaro for diabetes and Zepbound for weight-loss in the U.S., may see authorized generic versions. CEO David Ricks emphasized the need for India to enhance patent protection and eliminate redundant policies to attract global drugmaker investments. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 28, 2024 Category: Pharmaceuticals Source Type: news

Heartbeat unplugged: Addressing the silent epidemic of cardiovascular diseases through an Indian perspective
Prevention is key, and it's essential to address risk factors before symptoms develop when it comes to cardiovascular diseases, which is what makes the cardiac wellness session with Prof. (Dr) Ashok Seth and Dr. Ashwin B. Mehta, compelling. Delving deep into the world of heart health, these eminent cardiologists provided a medical handbook of cardiac wellness in the latest drop of the USV health awareness multimedia series—‘Heart Talks: A Deep Dive into Cardiac Wellness’—in collaboration with The Economic Times. Learn all about identifying commonly overlooked symptoms, the dominant risk factors, the role of early a...
Source: The Economic Times Healthcare and Biotech News - February 28, 2024 Category: Pharmaceuticals Source Type: news